GE HealthCare Reportedly in Talks for $1 Billion Acquisition of Sofie Biosciences
GE HealthCare is reportedly considering a potential $1 billion acquisition of Sofie Biosciences, according to Reuters citing sources. The deal would expand GEHC's access to radiotracers developed by Sofie and provide control over manufacturing operations in seven radiopharmacies producing F-18 FAPI-74. The companies already have a licensing agreement from 2023 granting global rights for certain compounds, but the acquisition could allow broader commercialization across markets. Sofie's ongoing Phase 3 trials for pancreatic and gastroesophageal cancer imaging add value to its development pipeline. However, without financial details like revenue or profit figures, it is difficult to assess whether the price tag aligns with potential returns. The deal would also bring operational responsibilities such as facility investment and staffing costs that could offset any additional earnings from manufacturing control. The commercial success of these radiotracers will depend on regulatory approval and market adoption.
Tickers: $GEHC
Topics: Acquisition Talks Healthcare Pharmaceuticals Radiopharmaceuticals